Browse the corpus

Common variable immunodeficiency (CVID) represents the most prevalent symptomatic primary immunodeficiency, characterized by impaired antibody production and broad clinical heterogeneity. Patients typically present with recurrent sinopulmonary infections, autoimmune disorders, granulomatous disease, gastrointestinal complications, and an elevated risk of malignancy. This course reviews the diverse underlying mechanisms of this disorder, including defects in B and T cell differentiation, monogenic mutations, polygenic susceptibility, and epigenetic dysregulation, as well as the genetic contributions that have been increasingly recognized, though most cases remain idiopathic. Participants will gain insights into management that relies heavily on immunoglobulin replacement therapy to reduce infections and improve survival. Additional interventions directed at autoimmune, pulmonary, gastrointestinal, and malignant complications are also discussed. This course explores the pathophysiology, diagnostic approach, and management of CVID, as well as genetic and immunologic underpinnings, clinical variability, diagnostic strategies, and treatment modalities. Optimal care requires accurate diagnosis, lifelong monitoring, and interprofessional collaboration to prevent morbidity and mortality. This activity for healthcare professionals is designed to enhance the learner's competence in recognizing diverse clinical presentations, differentiating CVID from secondary causes of hypogammaglobulinemia, initiating timely interventions, and implementing an appropriate interprofessional approach when managing CVID to enhance diagnostic accuracy, optimize patient outcomes, and support evidence-based, patient-centered management of this complex disorder. Objectives: Identify the characteristic clinical features of common variable immunodeficiency. Assess appropriate diagnostic strategies for CVID, including immunoglobulin measurement, vaccine response evaluation, and lymphocyte subset analysis. Implement evidence-based management strategies, including monitoring in patients with CVID. Collaborate with the interprofessional care team to provide coordinated care for patients with CVID to mitigate complications and improve long-term outcomes. Access free multiple choice questions on this topic.

Common variable immunodeficiency (CVID) represents the most common symptomatic primary immunodeficiency worldwide. The disorder arises from impaired antibody production caused by defects in B cell differentiation and function, often accompanied by abnormalities in T cell compartments and immune regulation.[1][2][3][4] Rather than constituting a single disease, CVID encompasses a heterogeneous group of conditions unified by hypogammaglobulinemia—characterized by reduced serum levels of IgG, typically decreased IgA, and occasionally low IgM—together with poor or absent specific antibody responses to immunizations or infections.[5] CVID displays marked variability in both clinical and immunological features. Patients frequently present with recurrent sinopulmonary infections, autoimmune manifestations, granulomatous inflammation, increased susceptibility to malignancy, and impaired antibody responses despite a normal or near-normal circulating B cell count.[6][7] The syndrome arises from a spectrum of genetic abnormalities, many of which remain unidentified. The term "variable" highlights the disorder’s broad range of clinical presentations and underlying molecular mechanisms.[6][8]

The etiology of CVID is highly heterogeneous and multifactorial, involving a complex interplay of genetic, epigenetic, and environmental factors. In most cases, a specific cause cannot be identified, and the disorder is considered idiopathic in 80% to 90% of patients.[4] Despite more than 4 decades of investigation, the primary cause of CVID remains unknown, although genetic contributions are well recognized.[9] Approximately 20% of CVID patients have a first-degree family member with a selective IgA deficiency, and 15% to 35% of cases are now attributed to monogenic defects, most commonly involving genes critical for B cell development, activation, and survival, such as TNFRSF13B (encoding TACI), NFKB1, NFKB2, ICOS, CD19, and others.[1][10][11] Specific examples include: Intrinsic B cell defects (CD19 deficiency due to mutations at 16p11.2) Intrinsic T cell defects (ICOS deficiency from mutations at 2q33) Mutations in TNF receptors, TACI or BAFFR deficiency from mutations in TNFRSF13B (17p11.2) and TNFRSF13C (22q13.1-q13.31), respectively [9][12][13][14] Other monogenic defects associated with CVID include deficiencies in MSH5, CD81, and CD20.[14] These mutations may be inherited or occur de novo, with variable penetrance and expressivity even within the same family. Nevertheless, many patients with CVID lack an identifiable genetic mutation.[15][16][11] CVID is increasingly recognized as a polygenic or oligogenic condition in which multiple low-penetrance variants affecting immune regulatory pathways interact to shape disease susceptibility and phenotype.[1][15][16][11] Epigenetic mechanisms, including DNA methylation changes, histone modifications, and microRNA dysregulation, further influence gene expression and contribute to immune cell dysfunction.[1][2] Most cases of CVID do not follow a clear pattern of inheritance. Documented inheritance modes include autosomal dominant with variable penetrance, autosomal recessive, and, in rare cases, X-linked transmission.

CVID is increasingly recognized as a polygenic or oligogenic condition in which multiple low-penetrance variants affecting immune regulatory pathways interact to shape disease susceptibility and phenotype.[1][15][16][11] Epigenetic mechanisms, including DNA methylation changes, histone modifications, and microRNA dysregulation, further influence gene expression and contribute to immune cell dysfunction.[1][2] Most cases of CVID do not follow a clear pattern of inheritance. Documented inheritance modes include autosomal dominant with variable penetrance, autosomal recessive, and, in rare cases, X-linked transmission. Environmental factors are also suspected to influence disease onset, although no consistent external triggers have been identified.[17] Overall, the pathogenesis of CVID spans a spectrum from monogenic defects to complex immune dysregulation. Abnormalities in B and T cell compartments, disruption of germinal center formation, and altered immune regulatory networks all contribute to the significant clinical and immunological heterogeneity of this disorder.[1][3][16][10][2]

CVID represents the most frequently diagnosed symptomatic primary immunodeficiency in clinical practice, although it remains rare overall. The estimated prevalence ranges from approximately 1 in 25,000 to 1 in 50,000 individuals in Europe and North America, with higher rates reported in northern Europe.[18][6][19][20][21] Certain Asian populations demonstrate lower prevalence, with Taiwan reporting 0.28 cases per 100,000 individuals.[21] CVID affects males and females equally, with no apparent racial predilection.[5][22] Onset may occur at any age, but most diagnoses are made after puberty, typically between ages 20 and 45, with peak incidence in the 20- to 40-year range.[6][19][8][5] Early-onset disease in individuals younger than 10 years of age is also recognized, particularly in males.[21] Diagnostic delays remain common, historically averaging 4 to 5 years, though improvements in awareness and immunological testing have shortened this timeframe in recent decades.[21][19] Most cases arise sporadically, although a minority follow familial patterns. Familial clustering is more common in populations with high consanguinity, where an autosomal recessive inheritance pattern may be suggested. Clinically, CVID presents with substantial heterogeneity, but recurrent sinopulmonary infections remain the most frequent manifestation. Many patients also experience noninfectious complications, eg, autoimmunity, lymphoproliferative disease, enteropathy, and malignancy.[8] These complications contribute to reduced life expectancy, particularly among patients who develop noninfectious manifestations.[8]

The pathophysiology of CVID is complex and heterogeneous, reflecting a final common pathway of hypogammaglobulinemia arising from multiple immunoregulatory defects.[6] The central immunologic hallmark of CVID is a defect in B-cell differentiation and function, resulting in impaired production of isotype-switched, affinity-matured antibodies.[2][23] This dysfunction originates from abnormalities in germinal center formation and function, which are essential for generating high-affinity class-switched memory B cells and plasma cells.[2][1][23] While the number of total B cells is typically normal in many patients, a reduced percentage of isotype-switched memory B cells capable of sustaining long-term antibody responses is noted.[23][24] Immunophenotypically, CVID also features an expansion of CD21low B cells, indicating a block in B cell maturation and selection.[23] High-throughput immunoglobulin heavy chain sequencing studies have demonstrated decreased V(D)J (variable, diversity, and joining gene segments) recombination diversity and reduced somatic hypermutation, further confirming a defect in antibody maturation.[23][23] Additional B-cell abnormalities include: Aberrant gene rearrangement and reduced diversity of the naïve B cell pool [23] Impaired signaling via Toll-like receptors 7 and 9 (TLR7, TLR9) in B cells and plasmacytoid dendritic cells, leading to diminished cytokine production and humoral responses [25][26][27][28] [28]Memory B cell subsets correlate with the following clinical features: Lower switched memory B cells are linked to splenomegaly, autoimmunity, lymphoid proliferation, and granulomatous disease. Low IgM memory B cells associate with bronchiectasis.[24][29][30][31][32][33][34] In some patients, B-cell defects are apparent as early as the pro-B cell stage, indicating a developmental block that occurs before the formation of germinal centers.[23] T cell abnormalities are also prominent, especially in patients with noninfectious complications, including: Reduced T regulatory cells (Tregs) [35] Increased T follicular helper (Tfh) cells [36] Loss of TCR repertoire diversity, often associated with thymic involution and failure of thymic output of naïve T cells [37][38] Additional T cell features reported in CVID include: Decreased proliferation to mitogens and antigens [6] Altered CD4/CD8 ratios, often due to CD4+ cell decline or CD8+ cell expansion [39]

Increased T follicular helper (Tfh) cells [36] Loss of TCR repertoire diversity, often associated with thymic involution and failure of thymic output of naïve T cells [37][38] Additional T cell features reported in CVID include: Decreased proliferation to mitogens and antigens [6] Altered CD4/CD8 ratios, often due to CD4+ cell decline or CD8+ cell expansion [39] Increased CD26 and CD30 levels (the latter linked to splenomegaly and malignancy) [40] Impaired T cell receptor signal transduction and reduced IL-12 production by dendritic cells [41] A drop in plasma cells within the bone marrow and gastrointestinal tract [24] At the molecular level, monogenic and polygenic defects in genes affecting B cell receptor signaling, costimulation, and intracellular pathways (eg, TNFRSF13B/TACI, ICOS, CD19, NFKB1, and NFKB2) have been implicated in CVID's immunological abnormalities.[2][1][3] Furthermore, epigenetic dysregulation, including alterations in DNA methylation and histone modification, as well as environmental influences (eg, microbial translocation from impaired gut barrier function), may contribute to immune cell dysfunction and clinical heterogeneity.[2][1][37]

Clinical Features Patients with CVID typically present with a history of recurrent infections, particularly affecting the upper and lower respiratory tracts, including sinusitis, otitis media, bronchitis, and pneumonia, which are often severe, persistent, or unusually frequent.[42][36][21][5] Sinopulmonary infections are common and may lead to bronchiectasis, which contributes to chronic productive cough, dyspnea, and obstructive lung disease.[43][44][45][46][42][21] Common organisms that cause these infections include Haemophilus influenzae, Streptococcus, Moraxella catarrhalis, and Staphylococcus aureus. Less frequently, patients present with septic arthritis, bacterial meningitis, sepsis, cutaneous infections, and, rarely, infections caused by Pneumocystis jirovecii or Mycoplasma pneumoniae.[44][45] Besides infections, noninfectious complications are common and may be the initial presentation, particularly in adults, including: Autoimmune cytopenias, eg, immune thrombocytopenia (10%–12%), coombs-positive autoimmune hemolytic anemia (5%–7%), and Evans syndrome [47][48] Rheumatoid arthritis (1%–10%), typically seronegative due to lack of autoantibody production [49] Systemic lupus erythematosus (rare with a frequency of <1%, and in some cases, remission correlates with a loss of B cells; flares may occur after the onset of hypogammaglobulinemia) [50] Autoimmune thyroiditis, Sjögren’s syndrome, vitiligo, sicca syndrome [47][51] Lymphoproliferative disorders, eg, lymphadenopathy and splenomegaly, often associated with autoimmunity or granulomatous disease, are also characteristic.[43][48] Granulomas may manifest in the lungs as parenchymal nodules or ground-glass opacities.[43][44] Gastrointestinal symptoms are frequent and heterogeneous, including: Chronic diarrhea and malabsorption due to Giardia, Clostridium difficile, bacterial enterocolitis, Cytomegalovirus, or Helicobacter pylori infection [44] Inflammatory bowel-like disease, sprue-like illness, pernicious anemia (10%), protein-losing enteropathy [52] Symptoms may precede diagnosis and lead to diagnostic delays [42][21] Skin manifestations are increasingly recognized, affecting up to 40% of patients, and may include: Recurrent skin infections (eg, abscesses, cellulitis, impetigo, warts) Eczema, vitiligo, and autoimmune cutaneous disorders [51] Alopecia areata or universalis, and cutaneous vasculitides such as polyarteritis nodosa [51][53]

Symptoms may precede diagnosis and lead to diagnostic delays [42][21] Skin manifestations are increasingly recognized, affecting up to 40% of patients, and may include: Recurrent skin infections (eg, abscesses, cellulitis, impetigo, warts) Eczema, vitiligo, and autoimmune cutaneous disorders [51] Alopecia areata or universalis, and cutaneous vasculitides such as polyarteritis nodosa [51][53] Liver involvement, including unexplained hepatomegaly and elevated liver enzymes, is a characteristic feature of the polyclonal infiltration phenotype.[43] Malignancies, particularly gastric carcinoma (risk increased up to 50-fold), and nonHodgkin lymphomas, are serious complications to be screened for regularly.[43][52] Clinical Phenotypes and Physical Findings Approximately 80% of patients with CVID present with a single dominant phenotype, while 12.6% display overlapping features.[43] Chapel and colleagues identified the following 5 principal phenotypes of CVID: Uncomplicated (infection-only) Autoimmunity Polyclonal lymphocytic infiltration (eg, lymphoid interstitial pneumonitis, hepatosplenomegaly, granulomas) Enteropathy (villous atrophy with lymphocytic infiltration) Lymphoid malignancy [43] Physical examination may appear normal in early stages but can reveal signs of chronic disease as the condition progresses. Findings may include nasal congestion from chronic sinusitis, scarring of tympanic membranes due to recurrent otitis, or evidence of bronchiectasis such as digital clubbing, crackles, dyspnea, and chronic cough. Additional manifestations include weight loss, night sweats, and fevers—so-called “B symptoms”—in patients with malignancy. Lymphadenopathy, splenomegaly, oral thrush, arthritis, and conjunctivitis may also be detected during evaluation.[54][42][36][48][51]

The evaluation of suspected CVID requires a structured, multistep process that incorporates clinical history, physical examination, laboratory testing, immunophenotyping, functional assays, and, in selected cases, genetic analysis. This approach confirms hypogammaglobulinemia, evaluates immune function, excludes secondary causes, and characterizes phenotypic variability to inform management strategies.[55][56][57][31][58] A detailed clinical history should document recurrent, severe, or unusual infections—especially those involving the sinopulmonary system—as well as noninfectious manifestations, eg, autoimmune cytopenias, lymphoproliferation, granulomatous disease, gastrointestinal involvement, and skin abnormalities.[55][56][57][59] Physical examination should assess lymphadenopathy, splenomegaly, signs of chronic lung disease (eg, clubbing or crackles), and dermatologic findings, including vitiligo, eczema, or alopecia.[59] Laboratory Studies Laboratory testing, primarily the measurement of serum immunoglobulin levels, remains the cornerstone of CVID diagnosis. Patients with CVID typically demonstrate significantly reduced IgG levels, accompanied by low IgA and IgM, with serum IgG often less than 400 mg/dL.[55][59] Routine evaluation includes complete blood counts every 3 to 6 months, Coombs testing for new anemia, and bone marrow biopsy with β2-microglobulin when lymphoma or myelodysplasia is suspected.[59] Additionally, diagnostic assessment of CVID includes evaluation of specific antibody responses. Impaired vaccine responses, measured after administration of protein-based vaccines (tetanus, diphtheria) or polysaccharide vaccines (pneumococcal), further confirm B-cell dysfunction. Isohemagglutinin titers may also be evaluated.[55][56][59]

Laboratory testing, primarily the measurement of serum immunoglobulin levels, remains the cornerstone of CVID diagnosis. Patients with CVID typically demonstrate significantly reduced IgG levels, accompanied by low IgA and IgM, with serum IgG often less than 400 mg/dL.[55][59] Routine evaluation includes complete blood counts every 3 to 6 months, Coombs testing for new anemia, and bone marrow biopsy with β2-microglobulin when lymphoma or myelodysplasia is suspected.[59] Additionally, diagnostic assessment of CVID includes evaluation of specific antibody responses. Impaired vaccine responses, measured after administration of protein-based vaccines (tetanus, diphtheria) or polysaccharide vaccines (pneumococcal), further confirm B-cell dysfunction. Isohemagglutinin titers may also be evaluated.[55][56][59] Flow cytometric immunophenotyping refines evaluation by assessing lymphocyte subsets. Many patients exhibit reduced isotype-switched memory B cells (CD27+, IgD−, IgM−), accompanied by the expansion of CD21low or transitional B cells. Abnormalities in CD4+ T cells, regulatory T cells, and an abnormal CD4/CD8 ratio may be found in patients with autoimmune or inflammatory features.[55][60][59][60] Classification schemes, eg, EUROclass, link these findings to clinical prognosis.[55][57] Functional assays, including memory B cell ELISpot, may be employed in specialized centers to measure differentiation into antibody-secreting cells.[55][56] Genetic Testing Genetic testing, although not required for diagnosis, supports evaluation in patients with early-onset disease, strong family history, or atypical presentations.[55][58][61] Results may identify monogenic defects and help guide prognosis or targeted therapy. Exclusion of secondary causes, eg, protein loss, drug-induced hypogammaglobulinemia, or malignancy, as well as other primary immunodeficiencies, is essential before confirming CVID.[55][56][57][31][58] System-Specific Evaluation

Genetic testing, although not required for diagnosis, supports evaluation in patients with early-onset disease, strong family history, or atypical presentations.[55][58][61] Results may identify monogenic defects and help guide prognosis or targeted therapy. Exclusion of secondary causes, eg, protein loss, drug-induced hypogammaglobulinemia, or malignancy, as well as other primary immunodeficiencies, is essential before confirming CVID.[55][56][57][31][58] System-Specific Evaluation Following diagnosis, system-specific evaluations are critical. Pulmonary assessment includes spirometry, diffusion studies, blood gas testing, chest radiography, and high-resolution computed tomography (CT) scans at baseline (approximately only 6% of patients have normal findings on high-resolution CT) and every 5 years.[62] Sputum cultures are performed as needed, with repeat testing every 6 to 12 months in patients with bronchiectasis to identify pathogens and determine antibiotic resistance.[63][64] Additionally, lung volume measurement is used to assess restrictive disease in patients who have an intolerance to exercise or who exhibit diffuse parenchymal lung disease on imaging. Bronchoscopy and bronchoalveolar lavage may identify suspected pulmonary granulomas, while magnetic resonance imaging (MRI) may be performed as a radiation-sparing alternative for lung evaluation or when clinically indicated.[59] Evaluation for lymphoproliferative disease should include abdominal imaging with ultrasound, CT, or MRI, along with lymph node biopsy when lymphoma is suspected.[59] Gastrointestinal assessment includes upper endoscopy with biopsy for Helicobacter pylori infection or malignancy screening at baseline, with repeat studies every 24 months in high-risk patients. Colonoscopy should be performed as indicated, and intestinal biopsies are warranted in patients with malabsorption, chronic diarrhea, or inflammatory symptoms.[59] Neurological evaluation requires a brain MRI and cerebrospinal fluid analysis in patients with suspected infectious or autoimmune neurological disease.[59] Skin or pulmonary biopsies may help exclude autoimmunity or malignancy in patients presenting with nodules, granulomas, or rashes. Long-Term Surveillance

Evaluation for lymphoproliferative disease should include abdominal imaging with ultrasound, CT, or MRI, along with lymph node biopsy when lymphoma is suspected.[59] Gastrointestinal assessment includes upper endoscopy with biopsy for Helicobacter pylori infection or malignancy screening at baseline, with repeat studies every 24 months in high-risk patients. Colonoscopy should be performed as indicated, and intestinal biopsies are warranted in patients with malabsorption, chronic diarrhea, or inflammatory symptoms.[59] Neurological evaluation requires a brain MRI and cerebrospinal fluid analysis in patients with suspected infectious or autoimmune neurological disease.[59] Skin or pulmonary biopsies may help exclude autoimmunity or malignancy in patients presenting with nodules, granulomas, or rashes. Long-Term Surveillance Long-term monitoring of plasma immunoglobulin levels remains essential: IgG, IgA, and IgM should be measured at diagnosis and every 6 months in patients receiving intravenous immunoglobulin replacement, or every 1 to 3 months in those treated with subcutaneous immunoglobulin replacement.

The cornerstone of CVID management involves lifelong immunoglobulin replacement therapy (IGRT), which significantly reduces the frequency and severity of infections, improves quality of life, and prolongs survival. Despite its high cost, IGRT lowers the burden of recurrent infections and their complications.[36][65][66][4][67][68][69] Immunoglobulin Replacement Therapy IGRT is indicated in patients with markedly low serum IgG levels, typically more than 2 standard deviations below the normal range, or those who have poor responses to protein and polysaccharide vaccines.[69] Therapy generally begins after the resolution of an active infection, with adequate hydration followed by a slow intravenous infusion load until tolerance develops, and then maintenance dosing is initiated. IVIG is typically administered at 300 to 600 mg/kg every 3 to 4 weeks, while subcutaneous IGRT (SCIG) is usually given weekly or biweekly. Selection depends on tolerability, lifestyle considerations, and access to care.[36][65][66][4][67][68] Treatment aims to maintain IgG trough levels above 700 to 800 mg/dL, with higher targets for patients with bronchiectasis or persistent infections.[36][65][66][4][67][68] Monitoring requires serum IgG measurement every 6 months, with dose adjustments based on clinical response, body weight, and serum levels.[70] Premedication with antihistamines (eg, diphenhydramine and acetaminophen) and occasionally hydrocortisone helps prevent infusion reactions.[69] Adverse effects from IVIG occur in 20% to 50% of patients, most frequently during the first infusion, and include headache, fever, chills, nausea, thromboembolic events, acute kidney injury, hemolytic anemia, and rarely anaphylaxis. Risk depends on dose, infusion rate, comorbidities, prothrombotic factors, and product brand. SCIG causes fewer systemic reactions but commonly produces local pain and swelling. Hydration and slow infusion rates minimize the risk of complications.[69] Patients with relatively higher IgG levels and only mild impairment of vaccine response may defer IGRT, provided they remain under close follow-up. Management of Infections

Treatment aims to maintain IgG trough levels above 700 to 800 mg/dL, with higher targets for patients with bronchiectasis or persistent infections.[36][65][66][4][67][68] Monitoring requires serum IgG measurement every 6 months, with dose adjustments based on clinical response, body weight, and serum levels.[70] Premedication with antihistamines (eg, diphenhydramine and acetaminophen) and occasionally hydrocortisone helps prevent infusion reactions.[69] Adverse effects from IVIG occur in 20% to 50% of patients, most frequently during the first infusion, and include headache, fever, chills, nausea, thromboembolic events, acute kidney injury, hemolytic anemia, and rarely anaphylaxis. Risk depends on dose, infusion rate, comorbidities, prothrombotic factors, and product brand. SCIG causes fewer systemic reactions but commonly produces local pain and swelling. Hydration and slow infusion rates minimize the risk of complications.[69] Patients with relatively higher IgG levels and only mild impairment of vaccine response may defer IGRT, provided they remain under close follow-up. Management of Infections Prompt treatment of bacterial infections is essential, often requiring antibiotic courses 2 to 3 times longer than standard regimens.[69]] Sputum culture or bronchoalveolar lavage should precede the initiation of antibiotics in respiratory infections.[69] Prophylactic antibiotics, such as azithromycin 250 mg 3 times per week, benefit patients with recurrent sinopulmonary infections despite IGRT.[66][71] Antiviral prophylaxis may be indicated during the influenza season for high-risk patients.[69] Autoimmune and Inflammatory Complications

Prompt treatment of bacterial infections is essential, often requiring antibiotic courses 2 to 3 times longer than standard regimens.[69]] Sputum culture or bronchoalveolar lavage should precede the initiation of antibiotics in respiratory infections.[69] Prophylactic antibiotics, such as azithromycin 250 mg 3 times per week, benefit patients with recurrent sinopulmonary infections despite IGRT.[66][71] Antiviral prophylaxis may be indicated during the influenza season for high-risk patients.[69] Autoimmune and Inflammatory Complications Autoimmune cytopenias, including immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA), respond first to glucocorticoids. Refractory disease may require rituximab or other immunosuppressants, while splenectomy remains a last-line option.[47][72][73][66][74] Granulomatous-lymphocytic interstitial lung disease (GLILD) often requires corticosteroids; however, steroid-sparing agents, eg, azathioprine, mycophenolate mofetil, rituximab, sirolimus, abatacept, or JAK inhibitors (based on case reports), may be necessary.[74][75] Enteropathy and other inflammatory organ involvement respond to immunosuppressants or biologics tailored to symptoms, with specialist guidance.[75] Rheumatologic conditions are managed according to standard protocols, with IGRT added in immunocompromised patients.[69] Malignancy Surveillance and Management Patients with CVID face increased risks of malignancy, particularly lymphoma and gastric carcinoma, which may occur at up to a 50-fold higher rate than in the general population.[52][69][76] Management follows standard oncologic protocols with close collaboration between immunology and oncology teams.[65][66][74] Routine cancer screening should align with national guidelines, although no CVID-specific surveillance schedule has been established. Testing for Helicobacter pylori and pernicious anemia is recommended due to their association with gastric cancer.[52] Hematopoietic stem cell transplantation may be considered in select cases of severe, refractory disease or malignancy.[66][75] Vaccinations

Patients with CVID face increased risks of malignancy, particularly lymphoma and gastric carcinoma, which may occur at up to a 50-fold higher rate than in the general population.[52][69][76] Management follows standard oncologic protocols with close collaboration between immunology and oncology teams.[65][66][74] Routine cancer screening should align with national guidelines, although no CVID-specific surveillance schedule has been established. Testing for Helicobacter pylori and pernicious anemia is recommended due to their association with gastric cancer.[52] Hematopoietic stem cell transplantation may be considered in select cases of severe, refractory disease or malignancy.[66][75] Vaccinations Vaccination strategies must reflect the degree of antibody deficiency.[77] Inactivated and subunit vaccines are recommended for both mild and severe cases, including DTaP, HBV, HAV, HIB, HPV, influenza, pneumococcal, inactivated polio, meningococcal, anthrax, rabies, intramuscular typhoid, and Japanese encephalitis vaccines. Live-attenuated vaccines are contraindicated in severe deficiencies but may be cautiously considered in mild cases, including MMR, varicella, rotavirus, herpes zoster, smallpox, and BCG. Household contacts should receive all appropriate non-live vaccines to reduce patient exposure risk.[69] Supportive and Interprofessional Care Pulmonary complications should be assessed and managed with input from pulmonologists.[69] Patients should not receive blood or blood components without Cytomegalovirus screening. Audiology monitoring helps detect sensorineural hearing loss.[78] Mental health support remains essential to address social isolation and chronic illness burden.[69] Regular dental care is critical, with prophylactic antibiotics required before invasive procedures. Genetic counseling should be offered to families with affected members.[69] Optimal care depends on an interprofessional team, including immunology, pulmonology, hematology, gastroenterology, and infectious disease specialists, working collaboratively to address the wide range of CVID complications and improve long-term outcomes.[65][66][68][69]

The differential diagnosis of CVID is broad and requires careful clinical, immunological, and, in some cases, genetic assessment. The starting point is the detection of hypogammaglobulinemia, which may be primary or secondary in origin and is not pathognomonic for CVID alone. Therefore, a stepwise exclusion of secondary causes and other primary immunodeficiencies is essential before confirming a CVID diagnosis. Secondary Hypogammaglobulinemia Before diagnosing CVID, secondary causes of low immunoglobulin levels must be ruled out, including the following decreased production and increased loss mechanisms: Decreased production causes Immunosuppressive therapies (eg, rituximab, corticosteroids) Malignancies (eg, chronic lymphocytic leukemia, multiple myeloma) Bone marrow suppression Chronic systemic diseases (eg, Goodpasture syndrome) [79][36] Increased loss causes Protein-losing enteropathies Nephrotic syndrome Extensive burns [79][36] Other Primary Immunodeficiencies Several primary immunodeficiency syndromes may present with similar immunologic or clinical features, including: X-linked agammaglobulinemia (Bruton disease) typically presents in early childhood, characterized by very low levels of immunoglobulins and the absence of B cells. Hyper-IgM syndromes: present with elevated or normal IgM, but low IgG and IgA. Selective IgA deficiency and IgG subclass deficiencies often cause recurrent infections, but without fulfilling CVID diagnostic criteria [80] Monogenic Immunodeficiencies with CVID-Like Phenotypes Some monogenic defects may clinically mimic CVID, particularly when associated with autoimmunity, enteropathy, or lymphoproliferation. Genetic testing is recommended in cases of early-onset, atypical, or familial disease, eg, CTLA4, LRBA, NFKB1, and NFKB2 mutations.[79][81] Autoimmune and Lymphoproliferative Disorders CVID frequently presents with autoimmune cytopenias, enteropathy, or lymphoid hyperplasia, which overlap with systemic autoimmune diseases, including: Systemic lupus erythematosus Sjögren’s syndrome Autoimmune lymphoproliferative syndrome (ALPS) Other connective tissue disorders [82][5] Importantly, the absence of autoantibodies (due to impaired antibody production) may obscure the diagnosis of autoimmune diseases in CVID patients. Gastrointestinal Disorders

CVID frequently presents with autoimmune cytopenias, enteropathy, or lymphoid hyperplasia, which overlap with systemic autoimmune diseases, including: Systemic lupus erythematosus Sjögren’s syndrome Autoimmune lymphoproliferative syndrome (ALPS) Other connective tissue disorders [82][5] Importantly, the absence of autoantibodies (due to impaired antibody production) may obscure the diagnosis of autoimmune diseases in CVID patients. Gastrointestinal Disorders CVID-associated enteropathy often mimics other chronic gastrointestinal diseases. Patients may present with features resembling celiac disease, although celiac-specific autoantibodies frequently remain absent. Other differential diagnoses include inflammatory bowel disease and chronic infectious enterocolitis. Histologic evaluation with biopsy may demonstrate nonspecific inflammatory changes rather than pathognomonic findings.[83] Malignancy Patients with CVID have a recognized risk of lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma. This malignancy can complicate CVID or present with clinical features that resemble primary autoimmune or immunodeficiency-related lymphoproliferation, underscoring the need for careful diagnostic distinction.[82][5] Summary and Diagnostic Strategy The protean manifestations of CVID—including recurrent infections, autoimmunity, enteropathy, and malignancy—demand a structured and interprofessional diagnostic approach. Essential steps include quantitative measurement of immunoglobulin levels, evaluation of vaccine responses, and flow cytometric analysis of B- and T-cell subsets. Exclusion of secondary causes must remain a priority, while targeted genetic testing should be performed in selected cases.[79][80][84][85][5] Accurate diagnosis depends on integrating clinical features with immunological data and recognizing overlapping presentations to prevent misclassification and optimize management.

The prognosis of CVID is highly variable and depends on multiple factors, including: Age at diagnosis Diagnostic delay Baseline immunoglobulin levels (especially IgA and IgG) The presence of noninfectious complications, eg, autoimmunity, chronic lung disease, lymphoproliferation, liver disease, and malignancy [67][86][87][8][21][88] Impact of Immunoglobulin Replacement Therapy The advent and widespread adoption of IGRT has significantly improved life expectancy in CVID. Before IGRT, survival often fell below 15 years after diagnosis, whereas current series report survival exceeding 50 years for many patients.[67] Deaths due to bacterial infections have declined dramatically with IGRT. Patients who experience only infectious complications demonstrate a 95% lower risk of death compared with those who develop noninfectious manifestations.[8][43] Noninfectious Complications and Mortality Despite advances in infection control, noninfectious complications remain the predominant cause of morbidity and mortality, affecting 60% to 70% of patients and contributing to an 11-fold increase in mortality risk.[21] These complications include granulomatous-lymphocytic interstitial lung disease (GLILD), autoimmune cytopenias, and systemic autoimmunity with a prevalence of 25%,[67][86][87][89] chronic liver disease, eg, nodular regenerative hyperplasia and cirrhosis, and malignancies, particularly nonHodgkin lymphoma and gastric cancer.[86][87][90][88][91] Outcomes following liver transplantation in CVID patients remain poor compared with other transplant populations.[86] Mortality Predictors and Prognostic Scoring The largest longitudinal cohort of CVID patients (473 individuals followed over 40 years in New York) identified pulmonary complications and malignancy as key predictors of mortality.[8][21][88] Other prognostic factors include: Higher age at diagnosis Longer diagnostic delay Marked reductions in IgA Low IgG and switched memory B cells, or elevated IgM, all of which correlate with autoimmunity, lymphoid hyperplasia, and pneumonia risk [90][92] The VISUAL score, a recently developed tool, helps stratify patients at diagnosis by predicting the likelihood of early severe complications and mortality.[93] In pediatric patients, 10-year survival after diagnosis approaches 71%, with worse outcomes observed in those who develop autoimmune disease or malignancies.[89] Overall Survival

The VISUAL score, a recently developed tool, helps stratify patients at diagnosis by predicting the likelihood of early severe complications and mortality.[93] In pediatric patients, 10-year survival after diagnosis approaches 71%, with worse outcomes observed in those who develop autoimmune disease or malignancies.[89] Overall Survival Overall mortality in CVID is estimated at approximately 20% compared with age- and sex-matched controls.[8] Malignant cells in CVID do not demonstrate greater resistance to therapy but appear more prone to dissemination, often necessitating aggressive treatments that may be poorly tolerated.[91] Although uncertainty remains regarding the role of IGRT in preventing noninfectious complications, its established benefit in reducing infectious morbidity has transformed the prognosis of CVID.[92]

CVID is associated with a broad spectrum of complications, which can be classified as infectious and noninfectious. While recurrent infections are hallmark features and often the first manifestation, noninfectious complications are now recognized as the major contributors to long-term morbidity and mortality.[94][65][5][4] In some patients, complications are the initial clinical presentation, while in others, they emerge later despite early diagnosis and immunoglobulin therapy, potentially shortening life expectancy. Pulmonary Complications Pulmonary disease is among the most common and impactful complications of CVID. Patients with respiratory symptoms should undergo evaluation using high-resolution CT to detect any structural abnormalities. The most frequent pulmonary complications include (in descending order of frequency): Bronchiectasis occurs in about 20% of cases (a structural airway abnormality resulting from recurrent bacterial infections and chronic inflammation) [21] Bronchospasm Obstructive and restrictive lung disease GLILD (often mimics sarcoidosis, and is associated with significant morbidity) [10][95][10] Autoimmune Complications Autoimmunity affects approximately 30% to 40% of CVID patients and may represent the first or only clinical feature.[84][96][81] The most frequent autoimmune manifestations include autoimmune cytopenias, eg, immune thrombocytopenia, autoimmune hemolytic anemia, and autoimmune neutropenia.[84][96][81] Additional autoimmune complications that may occur include: Arthritis, psoriasis, vitiligo Autoimmune thyroiditis, autoimmune gastritis Coeliac-like disease Primary biliary cholangitis [84][81] Lymphoproliferative and Granulomatous Disorders Lymphoproliferative and granulomatous disorders frequently complicate CVID and often overlap with autoimmunity. Presentations include persistent lymphadenopathy, splenomegaly, GLILD, and lymphoid hyperplasia.[10] Gastrointestinal Complications Gastrointestinal involvement develops in a substantial proportion of patients, ranging from mild to severe. Manifestations include chronic diarrhea, malabsorption, enteropathy with celiac-like features, inflammatory bowel disease (eg, colitis), chronic active or atrophic gastritis, and malignancies, eg, gastric and colorectal cancers, which may present at a younger age than in the general population.[36][97] Liver Disease

Gastrointestinal involvement develops in a substantial proportion of patients, ranging from mild to severe. Manifestations include chronic diarrhea, malabsorption, enteropathy with celiac-like features, inflammatory bowel disease (eg, colitis), chronic active or atrophic gastritis, and malignancies, eg, gastric and colorectal cancers, which may present at a younger age than in the general population.[36][97] Liver Disease Liver involvement continues to gain recognition in CVID. Nodular regenerative hyperplasia represents a significant complication, often leading to noncirrhotic portal hypertension. Abnormal liver function tests appear in a substantial subset of patients.[10] Malignancies CVID patients face a markedly increased risk of malignancy, estimated between 4% and 25%, with an actual incidence of approximately 10%, particularly in adults diagnosed later in life.[98][65][5] NonHodgkin lymphoma occurs in 2% to 8% of patients, most often B-cell type, frequently extranodal, and more common in females older than 30 years.[6][8][65][5][8] Gastric carcinoma also poses a significant risk, often linked to Helicobacter pylori infection and chronic gastritis. These tumors frequently appear as moderately to poorly differentiated intestinal-type adenocarcinomas with dense intra-tumoral lymphocyte infiltration.[97][36] Both lymphoma and gastric carcinoma represent leading causes of mortality in CVID.[94][65][5] Other Organ-Specific Complications Widespread immune dysregulation and heterogeneity in CVID contribute to additional complications, including endocrinopathies, neuropathies, and dermatologic disorders, eg, autoimmune and inflammatory skin diseases.[10] Pathogenesis and Risk Association The pathogenesis of these diverse complications reflects a multifactorial process involving antibody deficiency, immune dysregulation, cytokine imbalances, and, in some cases, monogenic defects.[10][81] The presence of noninfectious complications—particularly autoimmunity, lymphoproliferation, and malignancy—correlates strongly with poorer prognosis and increased mortality among CVID patients.[94][65][4]

Early diagnosis and lifelong management are key to improving outcomes in patients with CVID. Unfortunately, significant diagnostic delays—often ranging from 4 to 7 years—remain common due to the heterogeneous presentation and lack of awareness among patients and nonspecialist clinicians. Increasing public and clinical education is essential to overcoming these barriers. Patients and families must be educated that CVID is not a transient or curable condition, but rather a chronic immune disorder requiring consistent follow-up and treatment. Misconceptions about "curing" the disease with antibiotics or short-term therapies should be actively addressed. Clinicians should emphasize that IGRT is the cornerstone of treatment, not only to reduce infection frequency but also to improve long-term survival and quality of life. Educational initiatives should focus on recognizing early warning signs, eg, recurrent sinus or lung infections, unexplained autoimmune cytopenias, chronic diarrhea, or lymphadenopathy. Clinicians and patients must understand the role of IGRT, including its benefits, potential adverse effects, and the importance of strict adherence to prescribed dosing schedules. Infection prevention requires emphasis through vaccination strategies (excluding live vaccines when clinically appropriate), consistent hand hygiene, and prompt evaluation of new or concerning symptoms. Family screening or genetic counseling should be encouraged in patients with early-onset disease or those with a family history suggesting immune dysfunction. Counseling must also address psychosocial aspects of chronic immunodeficiency, including potential impacts on education, employment, and emotional well-being. A collaborative care team—comprising immunologists, primary care clinicians, nurses, and mental health professionals—should support patients in understanding their condition and encourage active engagement in their care. Early education and shared decision-making can enhance adherence, reduce complications, and empower patients to maintain healthier lives despite this lifelong disorder.

Key factors that should be kept in mind in the management of CVID include: Delayed recognition of this disease is a common occurrence. CVID may result from various gene defects. Opportunistic infections are rare but can occur. Several causes of hypogammaglobulinemia have to be excluded before determining the diagnosis of CVID. Higher doses of immune globulin are recommended for those patients with persistent infections. There is limited evidence of immune globulin therapy and its protective effects against malignancy. However, evidence suggests that treatment can slow the progression of pulmonary disease and reduce the frequency of certain infections. Also, it may offer protection against autoimmunity.

CVID, the most prevalent symptomatic primary immunodeficiency, presents as a complex multisystem disorder with highly heterogeneous manifestations. Patients may experience recurrent sinopulmonary infections, autoimmunity, granulomatous inflammation, gastrointestinal dysfunction, and an increased risk of malignancy. Due to this variability, diagnostic delays often occur, and misdiagnosis remains a common occurrence. Management requires a coordinated, interprofessional approach that integrates early recognition, targeted immunological testing, and long-term monitoring to optimize outcomes, reduce morbidity, and mitigate life-threatening complications. Physicians and advanced practitioners hold primary responsibility for recognizing clinical warning signs, conducting diagnostic evaluations, and coordinating longitudinal care. Immunologists refine diagnoses through vaccine response assessment, flow cytometry, and genetic testing, while nurses manage immunoglobulin replacement therapy, monitor adverse effects, and provide patient education on infection prevention and home therapy. Pharmacists optimize immunoglobulin dosing, identify potential drug interactions, and assist in planning prophylactic antimicrobial regimens. Mental health professionals, gastroenterologists, pulmonologists, and dietitians address psychosocial stressors, malignancy risk, and systemic complications. Effective management of CVID requires transparent interprofessional communication, shared decision-making, and structured care coordination. Regular team huddles, shared documentation, and cross-specialty case reviews ensure that subtle complications, such as anemia, chronic cough, or weight loss, are promptly identified. Collaborative oversight of immunoglobulin therapy schedules, vaccination planning, and malignancy surveillance reduces risks and improves safety. By fostering accountability and flattening the care hierarchy, interprofessional teams enhance continuity, minimize medical errors, and empower patients to engage in lifelong care actively.